Country: Olanda
Lingwa: Ingliż
Sors: HMA (Heads of Medicines Agencies)
canine parvovirus 5675 CCID50
Virbac S.A.
QI07AD01
Suspension for injection
Canine parvovirus vaccine
Dogs Non Food
2008-03-26
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 1. NAME OF THE VETERINARY MEDICINAL PRODUCT CANIGEN PUPPY 2b 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each dose of 1 ml contains ACTIVE SUBSTANCE: Live attenuated canine Parvovirus 2b Strain CPV39: 10 5.6 to 10 7,5 CCID 50 * * Cell culture infectious dose. EXIPIENTS: For a full list of excipients, see section 6.1 3. PHARMACEUTICAL FORM Colourless suspension for injection. 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Dog (puppy) 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES For active immunisation of dogs against canine parvovirosis, to reduce virus excretion, to prevent mortality and typical signs (enteric form) from the age of 5 weeks. The onset of protection occurs two weeks after vaccination. The duration of protection has been demonstrated until the age of 11 weeks. 4.3 CONTRAINDICATIONS None. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES The vaccinal strain can spread. It has been demonstrated that this spread did not cause adverse effects on pregnant or lactating females or cats. 4.5 SPECIAL PRECAUTIONS FOR USE SPECIAL PRECAUTIONS FOR USE IN ANIMALS The vaccine should be administered in accordance with the usual aseptic conditions for vaccination. Animals have to be treated for intestinal endoparasites prior to vaccination. Vaccinate only healthy puppies. In the case of high levels of maternal derived antibodies (>1/80) the seroconversion rate is reduced from 94% to 42%. SPECIAL PRECAUTIONS TO BE TAKEN BY THE PERSON ADMINISTERING THE VETERINARY MEDICINAL PRODUCT Aqra d-dokument sħiħ